Japan's Ministry of Health Labor and Welfare has expressed its opposition to several proposition for health care system changes set out in an interim report made by the Japanese government's Council for the Regulatory Reform.
Although the Council pointed out that the Ministry's goal to eliminate the drug-lag - the time between drug approvals in other developed countries and that in Japan - by the end of fiscal-year 2011 will not be attained because the number of reviewers with expertise cannot be increased instantly due to the fact that it takes a long time to train such specialists, the Ministry argued that it is not difficult for it to reach this objective by the deadline.
Already recruiting more reviewers
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze